ST段抬高型心肌梗死管理指南所依据的随机对照试验分析
该研究筛查了ACCF/AHA/SCAI关于ST段抬高型心肌梗死管理指南中引用的所有文献,纳入42项随机对照试验,计算其脆弱指数(FI)和脆弱商(FQ),并用Cochrane偏倚风险工具2.0评估偏倚风险,同时进行事后把握度分析。结果显示中位FI为10,FQ为0.0055;7项试验因随机化过程存在高偏倚风险,15项试验把握度不足。把握度充足的试验其FI和FQ均高于把握度不足的试验。作者结论支持在未来随机对照试验方法学中结合把握度分析使用FI和FQ分析。
要点
- 42项ST段抬高型心肌梗死指南引用的随机对照试验中,中位脆弱指数为10,脆弱商为0.0055。
- 7项试验存在高偏倚风险,全部归因于随机化过程中的偏倚。
- 15项试验把握度不足;把握度充足的试验其脆弱指数和脆弱商均高于把握度不足的试验。
- 作者认为未来随机对照试验方法学应结合把握度分析使用脆弱指数和脆弱商分析。
研究设计与关键结果
- 研究类型为对指南引用随机对照试验的方法学分析,纳入42项随机对照试验,评估其脆弱指数(FI)和脆弱商(FQ)。
- 中位脆弱指数为10,脆弱商为0.0055。
- 7项试验存在高偏倚风险,均因随机化过程中的偏倚;15项试验把握度不足。
- 把握度充足的试验其脆弱指数和脆弱商均高于把握度不足的试验。
证据类型、等级与局限
- 证据类型:对随机对照试验的方法学分析(指南引用试验的二次分析)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为未来随机对照试验方法学中应结合把握度分析使用脆弱指数和脆弱商分析。
- 作者认为理解和报告脆弱指数与脆弱商可使研究证据 readily available,并快速消除部分读者对可能研究局限性的担忧。
指南或共识出处
- ACCF/AHA/SCAI ST段抬高型心肌梗死管理指南
提炼说明
- 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The fragility index (FI) is calculated by iteratively changing one outcome "event" to a "non-event" within a trial until the associated p-value exceeds 0.05.
PURPOSE: To investigate the FI and fragility quotient (FQ) of trial endpoints referenced in the ACCF/AHA/SCAI guidelines in the management of ST-elevation myocardial infarctions. Secondarily, we assess the post-hoc power and risk of bias for these specific outcomes and whether differences exist between adequately and inadequately powered studies on fragility measures.
BASIC PROCEDURES: All citations referenced in the guideline were screened for inclusion criteria. The FI and FQ for all included trials were then calculated. The Cochrane 'risk of bias' Tool 2.0 was used to evaluate the likelihood and sources of bias in the included trials.
MAIN FINDINGS: Forty-two randomized controlled trials were included for assessment. The median FI was 10 with a FQ of 0.0055. Seven trials were at a high risk of bias, all due to bias in the randomization process. Fifteen trials were found to be underpowered. Adequately powered studies had higher FIs and FQs compared to underpowered studies.
PRINCIPAL CONCLUSIONS: Our findings support the use of FI and FQ analyses with power analyses in future methodology of randomized control trials. With understanding and reporting of FI and FQ, evidence of studies can be readily available and quickly eliminate some readers' concern for possible study limitations.
参考来源
- Meyer C, Bowers A, Jaiswal D, et al. An analysis of randomized controlled trials underpinning ST-elevation myocardial infarction management guidelines. Am J Emerg Med. 2019. PMID: 30940409. doi:10.1016/j.ajem.2019.03.038
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。